Transforming
oncology drug research & development paradigms

hero-img
Read more Contact us

Drug Portfolio

Asellus Therapeutics utilizes intelligently-designed tumor models to discover and develop novel oncology drugs.

Whole Tumor Biopsy

Tumor Resection

Greater patient diversity, Lower Autocrine Bias, Higher Throughput, Cost Savings

Increased patient diversity
(vs. CDX), PK/PD Studies,
Broader MoA

PDX surrogacy, in vitro-in vivo, fine tuning MoA, pharmacology

3D eX vivo Tumor Growth Assay (3DX-TGA)

Human Tumor Cells

Humanized TME

Murine & Human ECM

Patient-Derived Xenograft (PDX)

Human Tumor Cells

Murine TME

Murine ECM

Show info

Tumor Sample

Patient-sourced tumor material ensures minimal genetic and biologic drift in ex vivo preclinical model systems.

3DX-TGA Model

Advances in humanized 3D extracellular matrix (ECM)-based modeling resulted in ex vivo tumor establishment rates at over 90%. Asellus Therapeutics has established hundreds of patient tumor models across 16 distinct cancer indications.

Mouse PDX Model

Patient-derived xenografts (PDX) have increased the diversity of preclinical models. However, engraftment rate challenges and animal husbandry costs prevent larger uptake in the research community.

Science

Tumor Microenvironment (TME):
The normal cells, molecules, and blood vessels that surround and feed a tumor cell. A tumor can change its microenvironment, and the microenvironment can affect how a tumor grows and spreads.

Epithelial Tissue

Epithelia

Basement
membrane

Fibroblasts

Mesenchymal

Connective Tissue

O2 : CO2 Nutrients

Tumor Tissue

Low glucose

Inflammation

Low O2

Leaky
Vasculature

Show legend
  • epithelial
    Epithelial Cell
  • rbc
    Red Blood Cell (RBC)
  • ecm
    Activated ECM
  • mesenchymal
    Mesenchymal Cell
  • myeloid_green
    Myeloid Lineage Cell
  • carcinoma
    Tumor Cell (Carcinoma)
  • mutant-epithelial
    Mutant Epithelial Cell
  • lymphoid
    Lymphoid Lineage Cell
  • taf
    Tumor-Associated Fibroblast (TAF)

Genotype

  • Genetic Instability
  • Mutations / Deletions
  • Rearrangements
  • Host Genetics

Metabolism

  • Vasculature
  • Hypoxia (O2)
  • Glucose
  • pH

3D Environment

  • Architecture
  • Adhesions
  • Stiffness
  • ECM

Heterogeneous

  • Cellular Populations
  • Growth Factors
  • Chemokines
  • Cytokines

Pharmacology

  • Complex Networks
  • Tumor vs. Normal
  • Resistance
  • TME Disruption

3D(X)-TGA Model Evolution

Asellus Therapeutics is positioned as a leader in 3D model-based oncology drug discovery and development. Our 3D(X)-TGA models are fully embedded in Humanized murine tumor-derived extracellular matrix (ECM) and have evolved over 14+ years to better reflect the pathophysiology of human tumor microenvironments. These humanization efforts have created one of most advanced preclinical oncology platforms ever used.

Academia

Ohio State University (OH-US)

MD Anderson (TX-US)

University of Nottingham (UK)

Industry / Biotech

J&J

PRECOS

Molecular Response

3DX-TGA

Asellus Therapeutics

April 2017

 

 

 

Contact us

Asellus Therapeutics

11011 Torreyana Rd
Suite 190
San Diego, CA 92121

info@asellustherapeutics.com